Search in:

Leukemia & Lymphoma Volume 62, 2021 - Issue 4

Submit an article Journal homepage

Open access

4,457

Views

CrossRef citations to date

Altmetric

Original Articles

Safety and efficacy of navitoclax, a BCL-2 and BCL-X_L inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study

Sven de Vosa David Geffen School of Medicine at UCLA, Los Angeles, CA, USACorrespondence[email protected]
View further author information

John P. Leonardb Weill Cornell Medicine and New York-Presbyterian Hospital, New York, NY, USAView further author information

Jonathan W. Friedbergc Wilmot Cancer Institute, University of Rochester, Rochester, NY, USAView further author information

Jasmine Zaind City of Hope Comprehensive Cancer Center, Duarte, CA, USAView further author information

Kieron Dunleavye George Washington University, Washington, DC, USAView further author information

Rod Humerickhousef AbbVie, Inc, North Chicago, IL, USAView further author information

John Hayslipf AbbVie, Inc, North Chicago, IL, USAView further author information

John Peskof AbbVie, Inc, North Chicago, IL, USAView further author information

Wyndham H. Wilsone George Washington University, Washington, DC, USAView further author information

show all

Pages 810-818 | Received 11 Mar 2020, Accepted 26 Oct 2020, Published online: 25 Nov 2020

Cite this article
https://doi.org/10.1080/10428194.2020.1845332
CrossMark

Full Article
Figures & data
References
Supplemental
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

Citations (29)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (29)

Kimberly B. Johansson, Megan S. Zimmerman, Iryna V. Dmytrenko, Feng Gao & Daniel C. Link. (2023) Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia. Leukemia 37:12, pages 2356-2366.
Crossref

Wujun Chen, Yudong Wu, Jie Wang, Wanpeng Yu, Xin Shen, Kai Zhao, Bing Liang, Xiaokun Hu, Shuai Wang, Hongfei Jiang, Xinlin Liu, Miao Zhang, Xiaohui Xing, Chao Wang & Dongming Xing. (2023) Clinical advances in TNC delivery vectors and their conjugate agents. Pharmacology & Therapeutics, pages 108577.
Crossref

Himanshu N. Bhatt, Rimpy Diwan, Edgar A. Borrego, Carlos Alberto Martínez Pérez, Armando Varela-Ramirez, Raj Kumar, Renato J. Aguilera & Md Nurunnabi. (2023) A photothermal driven chemotherapy for the treatment of metastatic melanoma. Journal of Controlled Release 361, pages 314-333.
Crossref

Lea Miebach, Gabriella Melo‐Zainzinger, Eric Freund, Ramona Clemen, Alessandra Lourenco Cecchini & Sander Bekeschus. (2023) Medical Gas Plasma Technology Combines with Antimelanoma Therapies and Promotes Immune‐Checkpoint Therapy Responses. Advanced Science.
Crossref

Wonseon Ryu, Chul-Woo Park, Junghoon Kim, Hyungwoo Lee & Hyewon Chung. (2023) The Bcl-2/Bcl-xL Inhibitor ABT-263 Attenuates Retinal Degeneration by Selectively Inducing Apoptosis in Senescent Retinal Pigment Epithelial Cells. Molecules and Cells 46:7, pages 420-429.
Crossref

Sarubala Malayaperumal, Francesco Marotta, Makalakshmi Murali Kumar, Indumathi Somasundaram, Antonio Ayala, Mario Munoz Pinto, Antara Banerjee & Surajit Pathak. (2023) The Emerging Role of Senotherapy in Cancer: A Comprehensive Review. Clinics and Practice 13:4, pages 838-852.
Crossref

S. G. Chowdhury, S. Misra & Parimal Karmakar. (2023) Understanding the Impact of Obesity on Ageing in the Radiance of DNA Metabolism. The journal of nutrition, health & aging 27:5, pages 314-328.
Crossref

Florian Selt, Romain Sigaud, Gintvile Valinciute, Philipp Sievers, Julia Zaman, Clara Alcon, Simone Schmid, Heike Peterziel, Jessica W Tsai, Romain Guiho, Juan Pedro Martínez-Barbera, Stefan Pusch, Jing Deng, Yifan Zhai, Cornelis M van Tilburg, Martin U Schuhman, Ahmed El Damaty, Pratiti Bandopadhayay, Christel Herold-Mende, Andreas von Deimling, Stefan M Pfister, Joan Montero, David Capper, Ina Oehme, Felix Sahm, David T W Jones, Olaf Witt & Till Milde. (2023) BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma. Neuro-Oncology 25:4, pages 735-747.
Crossref

Arnab Sarkar, Abhik Paul, Tanmoy Banerjee, Avik Maji, Sanjukta Saha, Anupam Bishayee & Tapan Kumar Maity. (2023) Therapeutic advancements in targeting BCL-2 family proteins by epigenetic regulators, natural, and synthetic agents in cancer. European Journal of Pharmacology 944, pages 175588.
Crossref

Thomas E. Lew and & John F. Seymour. 2023. Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies. Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies 165 185 .

Elisabeth A. Lasater, Dhara N. Amin, Rajat Bannerji, Raghuveer Singh Mali, Kathy Barrett, Ryan N. Rys, Jason Oeh, Eva Lin, Tim Sterne‐Weiler, Ellen Rei Ingalla, MaryAnn Go, Shang‐Fan Yu, Maxwell M. Krem, Chris Arthur, Uwe Hahn, Anna Johnston, Vinit Karur, Nadia Khan, Paula Marlton, Tycel Phillips, Giuseppe Gritti, John F. Seymour, Monica Tani, Sam Yuen, Scott Martin, Matthew T. Chang, Christopher M. Rose, Victoria C. Pham, Andrew G. Polson, YiMeng Chang, Claudia Wever, Nathalie A. Johnson, Yanwen Jiang, Jamie Hirata, Deepak Sampath, Lisa Musick, Christopher R. Flowers & Ingrid E. Wertz. (2023) Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study. American Journal of Hematology 98:3, pages 449-463.
Crossref

Pooi-Fong Wong, Murugan Dharmani & Thamil Selvee Ramasamy. (2023) Senotherapeutics for mesenchymal stem cell senescence and rejuvenation. Drug Discovery Today 28:1, pages 103424.
Crossref

Thomas E. Lew & John F. Seymour. (2022) Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination. Journal of Hematology & Oncology 15:1.
Crossref

Vijaya Bharti, Reese Watkins, Amrendra Kumar, Rebecca L. Shattuck-Brandt, Alexis Mossing, Arjun Mittra, Chengli Shen, Allan Tsung, Alexander E. Davies, Walter Hanel, John C. Reneau, Catherine Chung, Gina M. Sizemore, Ann Richmond, Vivian L. Weiss & Anna E. Vilgelm. (2022) BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis. Cell Reports 41:12, pages 111826.
Crossref

Uly Sumarni, Jiaqi Zhu, Tobias Sinnberg & Jürgen Eberle. (2022) Sensitivity of Cutaneous T-Cell Lymphoma Cells to the Mcl-1 Inhibitor S63845 Correlates with the Lack of Bcl-w Expression. International Journal of Molecular Sciences 23:20, pages 12471.
Crossref

Yu Sun, Qingfeng Li & James L Kirkland. (2022) Targeting senescent cells for a healthier longevity: the roadmap for an era of global aging. Life Medicine 1:2, pages 103-119.
Crossref

Benjamin Sobol, Osama Azzam Nieto, Emily Lara Eberlein, Anna-Lena Scherr, Lars Ismail, Annika Kessler, Luisa Nader, Maximilian Schwab, Paula Hoffmeister, Nathalie Schmitt, Dirk Jäger, Stefan Welte, Katharina Seidensaal, Petros Christopoulos, Christoph Heilig, Katharina Kriegsmann, Stefan Fröhling, Mark Kriegsmann, Jochen Hess & Bruno Christian Köhler. (2022) Specific Targeting of Antiapoptotic Bcl-2 Proteins as a Radiosensitizing Approach in Solid Tumors. International Journal of Molecular Sciences 23:14, pages 7850.
Crossref

Myriam Salazar-Terreros & Jean-Paul Vernot. (2022) In Vitro and In Vivo Modeling of Normal and Leukemic Bone Marrow Niches: Cellular Senescence Contribution to Leukemia Induction and Progression. International Journal of Molecular Sciences 23:13, pages 7350.
Crossref

Florian Hagenbourger, Sheila Bohler & Miriam Erlacher. (2022) No time to die? Intrinsic apoptosis signaling in hematopoietic stem and progenitor cells and therapeutic implications. Current Opinion in Hematology 29:4, pages 181-187.
Crossref

Bárbara Pinto, Pedro Novais, Ana C. Henriques, Juliana Carvalho-Tavares, Patrícia M. A. Silva & Hassan Bousbaa. (2022) Navitoclax Enhances the Therapeutic Effects of PLK1 Targeting on Lung Cancer Cells in 2D and 3D Culture Systems. Pharmaceutics 14:6, pages 1209.
Crossref

Justyna Derebas, Kinga Panuciak, Mikołaj Margas, Joanna Zawitkowska & Monika Lejman. (2022) The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients. Cancers 14:6, pages 1569.
Crossref

Andrea Lopez, Denis E. Reyna, Nadege Gitego, Felix Kopp, Hua Zhou, Miguel A. Miranda-Roman, Lars Ulrik Nordstrøm, Swathi-Rao Narayanagari, Ping Chi, Eduardo Vilar, Aristotelis Tsirigos & Evripidis Gavathiotis. (2022) Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer. Nature Communications 13:1.
Crossref

Anna Kawiak & Anna Kostecka. (2022) Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy. Cancers 14:2, pages 279.
Crossref

Jessalyn Low, Brian Chan & Andy Tay. (2021) Targeted Therapeutics Delivery by Exploiting Biophysical Properties of Senescent Cells. Advanced Functional Materials 32:2.
Crossref

Paul A. Townsend, Maria V. Kozhevnikova, Olivier N. F. Cexus, Andrey A. ZamyatninJrJr & Surinder M. Soond. (2021) BH3-mimetics: recent developments in cancer therapy. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref

Nathan S. Gasek, George A. Kuchel, James L. Kirkland & Ming Xu. (2021) Strategies for targeting senescent cells in human disease. Nature Aging 1:10, pages 870-879.
Crossref

Pataje G Prasanna, Deborah E Citrin, Jeffrey Hildesheim, Mansoor M Ahmed, Sundar Venkatachalam, Gabriela Riscuta, Dan Xi, Guangrong Zheng, Jan van Deursen, Jorg Goronzy, Stephen J Kron, Mitchell S Anscher, Norman E Sharpless, Judith Campisi, Stephen L Brown, Laura J Niedernhofer, Ana O’Loghlen, Alexandros G Georgakilas, Francois Paris, David Gius, David A Gewirtz, Clemens A Schmitt, Mohamed E Abazeed, James L Kirkland, Ann Richmond, Paul B Romesser, Scott W Lowe, Jesus Gil, Marc S Mendonca, Sandeep Burma, Daohong Zhou & C Norman Coleman. (2021) Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy. JNCI: Journal of the National Cancer Institute 113:10, pages 1285-1298.
Crossref

Xiaofeng Dai, Danjun Wang & Jianying Zhang. (2021) Programmed cell death, redox imbalance, and cancer therapeutics. Apoptosis 26:7-8, pages 385-414.
Crossref

Claudia Hamilton, Jennifer P. Fox, Daniel B. Longley & Catherine A. Higgins. (2021) Therapeutics Targeting the Core Apoptotic Machinery. Cancers 13:11, pages 2618.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Safety and efficacy of navitoclax, a BCL-2 and BCL-X_L inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study

Articles from other publishers (29)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study

Citations (29)

Articles from other publishers (29)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Safety and efficacy of navitoclax, a BCL-2 and BCL-X_L inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study